Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Aradigm Announces Second Quarter 2012 Financial Results

Press Releases

<< Back
Aug 09, 2012

Aradigm Announces Second Quarter 2012 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2012.

Total revenue was approximately $0.2 million for both the second quarter of 2012 and the second quarter of 2011. Revenue in both quarters reflects the quarterly royalty payment from Zogenix for product sales of SUMAVEL® DosePro™ needle-free delivery system for treatment of acute migraine and cluster headaches.

The Company's net loss for the second quarter of 2012 was approximately $1.8 million, or $0.01 per share, compared with a net loss of approximately $2.9 million, or $0.02 per share, for the second quarter of 2011. Total operating expenses for the second quarter of 2012 were approximately $1.6 million, compared with total operating expenses of approximately $3.0 million for the second quarter of 2011. The decrease in operating expenses was primarily due to lower clinical costs for the inhaled ciprofloxacin program versus the prior year period.

As of June 30, 2012, cash, cash equivalents and short-term investments totaled approximately $5.6 million.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of respiratory and other diseases in tobacco smokers through smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements, including, but not limited to, statements regarding the product development efforts for the inhaled ciprofloxacin program and continued receipt of royalties from Zogenix, Inc. These forward-looking statements involve risk and uncertainties, as well as the other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on March 28, 2012, and the Company's Quarterly Reports on Form 10-Q.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

 

ARADIGM CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 
  Three months ended

June 30,

    Six months ended

June 30,

2012 2011 2012 2011
 
Revenues $ 240   $ 184   $ 522   $ 366  
Operating expenses:
Research and development 700 1,584 1,486 3,064
General and administrative 913 1,440 1,996 2,575
Restructuring and asset impairment 9 10 18 20
       
Total operating expenses   1,622     3,034     3,500     5,659  
 
Loss from operations (1,382 ) (2,850 ) (2,978 ) (5,293 )
 
Interest income 3 1 7 3
Interest expense (382 ) (46 ) (752 ) (53 )
Other income (expense), net - 1 2 2
       
Net loss $ (1,761 ) $ (2,894 ) $ (3,721 ) $ (5,341 )
Change in unrealized losses on available-for-sale securities - - (1 ) -
Comprehensive loss $ (1761 ) $ (2,894 ) $ (3,722 ) $ (5,341 )
Basic and diluted net loss per common share $ (0.01 ) $ (0.02 ) $ (0.02 ) $ (0.03 )
 
Shares used in computing basic and diluted net loss per common share   198,406     170,731     198,166     170,435  
 
 

ARADIGM CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 
  June 30,

2012

    December 31,

2011

(Unaudited)     *
ASSETS
Current assets:
Cash and cash equivalents $ 3,808 $ 2,148
Short-term investments 1,794 6,516
Receivables 53 36
Prepaid and other current assets 212 161
       
Total current assets 5,867 8,861
Property and equipment, net 913 1,113
Notes receivable - 29
Other assets 518 553
       
Total assets $ 7,298       $ 10,556
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $ 195 $ 196
Accrued clinical and cost of other studies 241 247
Accrued compensation 292 195
Facility lease exit obligation 132 120
Other accrued liabilities   78         86
 
Total current liabilities 938 844
Deferred rent 144 132
Facility lease exit obligation, non-current 545 609
Other non-current liabilities - 75
Note payable, net of discount and accrued interest 8,387 8,207
Shareholders' equity (deficit) (2,716 ) 689
       
Total liabilities and shareholders' equity (deficit) $ 7,298       $ 10,556

* The balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Source: Aradigm Corporation

News Provided by Acquire Media

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.